AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$TAK

Plump Andrew Stewart sold $363K of TAK (indirect holdings)

Plump Andrew Stewart (President, R&D) sold 19,651 indirectly-held shares of TAKEDA PHARMACEUTICAL CO LTD (TAK) at $18.49 ($0.36M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Plump Andrew Stewart
Published Aug 21, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TAK
Neutral
high confidence
Mentioned
$TAK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TAKNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming R&D milestones not reflected in this filing.

Relevance 3/10Novelty 4/10Timing: filing today

Background

SEC Form 4 filing reports insider transaction for Takeda Pharmaceutical.

Company-level read

Ticker impact

$TAKNeutralHigh confidence
Context

Form 4 disclosed President of R&D sold 19,651 shares for $363,346 via 10b5-1 plan.

Expected impact

Limited impact; price likely unchanged.

Evidence & confidence

Sale amount <$1M and typical for insiders; no material change to ownership.

Market effects

Sector

No broader sector impact; Takeda remains unchanged in pharma sector.

Regional

None

Global

Minimal

Counterpoint

What could challenge this read

Insider sell could be routine; investors may ignore.

Key entities

  • Company
    Takeda Pharmaceutical Co Ltd

    Japanese pharma company listed on NYSE as TAK.

  • Person
    Plump Andrew Stewart

    President, R&D at Takeda; insider seller.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TAK insider trading history →

Related articles

OCT 26
$AZNMedAI 8/10

AstraZeneca: Stomach Cancer Drug With $3 to $5 Billion Sales Potential, and One Significant Wrinkle

AstraZeneca (AZN) reported that its drug sone-ve doubled median survival in stomach cancer patients who had already tried at least two treatments, with median survival rising from 5.0 to 10.0 months. The company expects peak annual sales of $3B to $5B. Takeda (TAK) also reported positive results for its rival drug, arcotatug tavatecan, meeting both primary endpoints.

finance.yahoo.com3 min
OCT 23
$TAKHighAI 9/10

Takeda reports positive phase 3 trial results for gastric cancer drug

Takeda Pharmaceutical (TSE:4502/NYSE:TAK) reported positive Phase 3 trial results for arcotatug tavatecan in gastric cancer patients, meeting overall and progression-free survival endpoints. Median overall survival was 10.2 months vs. 6.9 months for other treatments. The drug showed a 37.4% objective response rate. Takeda plans regulatory filings in Japan and China. The drug is not yet approved by the FDA.

investing.com2 min
OCT 19
$TAKLowAI 8/10

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda's VERDICT trial showed that treating ulcerative colitis patients with ENTYVIO to achieve disease clearance (vs. symptomatic remission) prolonged time to complications by 70%. The study met its primary endpoint, with Group 3 (disease clearance) showing longer time to complications (HR 0.33, P=0.0014). Over 50% of patients in Group 3 achieved their target by Week 16. The trial also identified molecular patterns associated with early disease clearance.

elliotlakestandard.ca2 min